trending Market Intelligence /marketintelligence/en/news-insights/trending/aimhvzf3rpcvwmd-jlki6q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Boston Scientific to acquire privately held NxThera

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Boston Scientific to acquire privately held NxThera

Marlborough, Mass.-based Boston Scientific Corp. entered an agreement to acquire privately held NxThera Inc.

Boston Scientific will add NxThera's Rezum system to its existing portfolio of laser therapy systems for the treatment of a non-cancerous prostate enlargement condition called benign prostatic hyperplasia, or BPH.

BPH affects 110 million men worldwide, and more than 12 million symptomatic men in the U.S. are being treated for the condition with medications or procedural approaches, according to Boston Scientific.

The transaction consists of an upfront cash payment of $306 million and up to an additional $100 million in potential commercial milestone payments over the next four years. However, because Boston Scientific already owns a minority stake in the medical device company, it will only pay $240 million up front and up to $85 million in milestone-related payments.

The Rezum system was cleared by the U.S. Food and Drug Administration in 2015 and has the CE mark in EU.

The acquisition is expected to contribute toward Boston Scientific's adjusted earnings per share after 2020 and will close in the second quarter of 2018.